Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 201–300 of 2,162
Butt, A. Q., & Mills, K. H. G. (2014) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 140
Immunotoxicity of monoclonal antibodies
Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140
Hypercytokinaemia accompanies HIV–tuberculosis immune reconstitution inflammatory syndrome
Tadokera, R., Meintjes, G., Skolimowska, K. H., Wilkinson, K. A., Matthews, K., Seldon, R., Chegou, N. N., Maartens, G., Rangaka, M. X., Rebe, K. B., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00091010 · Cited by 160
“The experimental drug TGN1412 also caused serious acute illness likely to be driven by cytokines when given to six participants in a Phase I trial [35].”
BackgroundPhase I trials as valid therapeutic options for patients with cancer
Adashek, J. J., LoRusso, P. M., Hong, D. S., & Kurzrock, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0262-9 · Cited by 146
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation
Zou, P., Yu, Y., Zheng, N., Yang, Y., Paholak, H. J., Yu, L. X., & Sun, D. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9332-y · Cited by 138
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133
“TGN1412, an anti-CD28 superagonist monoclonal antibody that induced a life-threatening cytokine storm in the first human clinical patients pointing to the importance of species relevance (4), is likely to make development of such biotechnology compounds even more complicated (5).”
BackgroundRole of PD-1 in HIV Pathogenesis and as Target for Therapy
Porichis, F., & Kaufmann, D. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0106-4 · Cited by 159
Why we need easy access to all data from all clinical trials and how to accomplish it
Gøtzsche, P. C. (2011) · Trials · doi:10.1186/1745-6215-12-249 · Cited by 137
“This can only occur if the industry discloses all protocols, results and raw data from all studies in humans, including those in non-patient volunteers who may also suffer the harm of the drugs [11,114].”
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 170
Cancer and Aging - the Inflammatory Connection
Zinger, A., Cho, W. C., & Ben-Yehuda, A. (2017) · Aging and disease · doi:10.14336/ad.2016.1230 · Cited by 136
“Nat Rev Clin Oncol, 11: 630-632 [123] Suntharalingam G, Perry MR, Ward S, Brett SJ,”
BackgroundStress: Concepts, Definition and History☆
Fink, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.02208-2 · Cited by 194
Choi, B. D., Kuan, C., Cai, M., Archer, G. E., Mitchell, D. A., Gedeon, P. C., Sanchez-Perez, L. A., Pastan, I. H., Bigner, D. D., & Sampson, J. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219817110 · Cited by 142
“To avoid the complex preparation required for cell-based therapy, T cells instead can be activated in vivo by agonistic antibodies, which obviates the need for clonal T-cell survival and expansion; however, this approach indiscriminately activates circulating T cells throughout the body, producing disastrous autoimmun…”
BackgroundIn the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy
Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 144
Autonomy, Rationality, and Contemporary Bioethics
Pugh, J. (2020) · doi:10.1093/oso/9780198858584.001.0001 · Cited by 195
Diamanti, A. P., Rosado, M. M., Pioli, C., Sesti, G., & Laganà, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093330 · Cited by 141
“CRS has been under tight evaluation since it caused the admission to the intensive care unit of six healthy individuals enrolled in the phase I trial for the anti-CD28 mAb TGN1412A in 2006 [9].”
BackgroundAtkins, J. T., George, G. C., Hess, K., Marcelo-Lewis, K. L., Yuan, Y., Borthakur, G., Khozin, S., LoRusso, P., & Hong, D. S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01033-x · Cited by 132
Pastor, F., Kolonias, D. S., McNamara, J. O., & Gilboa, E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.145 · Cited by 139
Is TRAIL the holy grail of cancer therapy?
Newsom-Davis, T. E., Prieske, S., & Walczak, H. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0321-2 · Cited by 151
“known [163].”
Davila, M. L., & Brentjens, R. J. (2016) · PubMed · Cited by 151
The role of gut microbiota in T cell immunity and immune mediated disorders
Shim, J. A., Ryu, J. H., Jo, Y., & Hong, C. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.79430 · Cited by 155
“Thus, experimental results using gnotobiotic mouse models in the drug development stage cannot fully represent humans [21].”
A Framework for Risk-Benefit Evaluations in Biomedical Research
Rid, A., & Wendler, D. S. (2011) · Kennedy Institute of Ethics journal · doi:10.1353/ken.2011.0007 · Cited by 147
“Moreover, the fact that the public has had strongly negative responses to deaths or severe adverse events in studies that offered no potential clinical benefits for participants—for example, to the death of Ellen Roche, a healthy volunteer in a study investigating the pathophysiology of asthma (Steinbrook 2002), and t…”
BackgroundClinical development methodology for infusion‐related reactions with monoclonal antibodies
Doessegger, L., & Banholzer, M. L. (2015) · Clinical & Translational Immunology · doi:10.1038/cti.2015.14 · Cited by 127
Wang, J., Takeuchi, H., Sonobe, Y., Jin, S., Mizuno, T., Miyakawa, S., Fujiwara, M., Nakamura, Y., Kato, T., Muramatsu, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709592105 · Cited by 129
Ip, B., Cilfone, N. A., Belkina, A. C., DeFuria, J., Jagannathan‐Bogdan, M., Zhu, M., Kuchibhatla, R., McDonnell, M. E., Xiao, Q., Kepler, T. B., et al. (2016) · Obesity · doi:10.1002/oby.21243 · Cited by 127
“Both CD4(1) and CD8(1) T cells are implicated in IR/type 2 diabetes mellitus (T2DM), but the clinical usefulness of these observations is limited by risks that accompany T cell manipulation (7,8).”
BackgroundImpact of Immune-Modulatory Drugs on Regulatory T Cell
Furukawa, A., Wisel, S. A., & Tang, Q. (2016) · Transplantation · doi:10.1097/tp.0000000000001379 · Cited by 137
“Although agonist anti-CD28 mAbs in rodents show preferential augmentation of Treg and therapeutic efficacy in autoimmune diseases, an early human trial revealed life-threatening cytokine storm in healthy volunteers after receiving agonist anti-CD28 mAb.(221) Monovalent anti-CD28 Fab lacking an Fc region abrogates agon…”
BackgroundNolan, A., Kobayashi, H., Naveed, B., Kelly, A., Hoshino, Y., Hoshino, S., Karulf, M., Rom, W. N., Weiden, M. D., & Gold, J. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006600 · Cited by 145
“Finally, these data support the recent observations of lethal cytokine storm in with administration of an agonist CD28 antibody in humans [25].”
ResultCD28 Aptamers as Powerful Immune Response Modulators
Pastor, F., Soldevilla, M. M., Villanueva, H., Kolonias, D., Inoges, S., de Cerio, A. L., Kandzia, R., Klimyuk, V., Gleba, Y., Gilboa, E., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.26 · Cited by 125
Clinical pharmacology considerations for the development of immune checkpoint inhibitors
Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124
Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy
Amatore, F., Gorvel, L., & Olive, D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1693540 · Cited by 130
Antibody engineering and modification technologies
Filpula, D. R. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.03.004 · Cited by 156
Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models
Wnorowski, A., Yang, H., & Wu, J. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.001 · Cited by 124
Translating costimulation blockade to the clinic: lessons learned from three pathways
Ford, M. L., & Larsen, C. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00776.x · Cited by 123
“These results are particularly important given the tragic results of a phase I clinical trial in humans earlier this year (26), where six healthy volunteers experienced a systemic inflammatory response following administration of an agonistic anti-CD28 mAb (26).”
ResultFc-engineered antibodies with immune effector functions completely abolished
Wilkinson, I. C., Anderson, S., Fry, J. W., Julien, L. A., Neville, D. C. A., Qureshi, O. S., Watts, G., & Hale, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260954 · Cited by 134
Na, S., Mracsko, E. Z., Liesz, A., Hünig, T., & Veltkamp, R. C. (2014) · Stroke · doi:10.1161/strokeaha.114.007756 · Cited by 128
“sequent to the disastrous cytokine release syndrome observed in a phase 1 study.(30)”
BackgroundKnorr, D. A., Dahan, R., & Ravetch, J. V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810566115 · Cited by 120
“Although several aspects of the clinical trial design were suboptimal with TGN1412, the major toxicity of massive cytokine release syndrome was missed in both in vitro and nonhuman primate toxicology models.”
BackgroundInfluentialInsights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Naturalizing mouse models for immunology
Graham, A. L. (2021) · Nature Immunology · doi:10.1038/s41590-020-00857-2 · Cited by 131
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
Schaer, D. A., Hirschhorn-Cymerman, D., & Wolchok, J. D. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-7 · Cited by 119
Krämer, T. J., Hack, N., Brühl, T. J., Menzel, L., Hummel, R., Griemert, E.-V., Klein, M., Thal, S. C., Bopp, T., & Schäfer, M. K. E. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1550-0 · Cited by 119
Engineering inkjet bioprinting processes toward translational therapies
Angelopoulos, I., Allenby, M. C., Lim, M., & Zamorano, M. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27176 · Cited by 122
Preclinical safety testing of monoclonal antibodies: the significance of species relevance
Chapman, K., Pullen, N., Graham, M., & Ragan, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2242 · Cited by 121
“However, as recently shown by the clinical effects observed for TGN1412, an anti-CD28 super-agonist mA”
BackgroundHeterogeneity in the initiation, development and function of type 2 immunity
Gause, W. C., Rothlin, C., & Loke, P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0301-x · Cited by 119
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Singh, A. K., Dees, S., & Grewal, I. S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01225-5 · Cited by 127
Dendritic cell vaccines in melanoma: From promise to proof?
Lesterhuis, W. J., Aarntzen, E. H. J. G., de Vries, I. J. M., Schuurhuis, D. H., Figdor, C. G., Adema, G. J., & Punt, C. J. A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.007 · Cited by 124
“The recent unexpected results with the anti-CD28 monolonal antibody TGN1412 again demonstrated the enormous otency of drugs that manipulate the co-stimulatory pathays [158,159].”
BackgroundStudying immunity to zoonotic diseases in the natural host — keeping it real
Bean, A. G. D., Baker, M. L., Stewart, C. R., Cowled, C. J., Deffrasnes, C., Wang, L., & Lowenthal, J. W. (2013) · Nature reviews. Immunology · doi:10.1038/nri3551 · Cited by 142
“Furthermore, there are many examples of successful preclinical trials of immunomodulatory drugs or vaccines in mice that have failed to translate into successful clinical trials in humans [15] [16] [17] .”
BackgroundImmune cartography of macrophage activation syndrome in the COVID-19 era
McGonagle, D., Ramanan, A. V., & Bridgewood, C. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00571-1 · Cited by 123
Respiratory syncytial virus vaccine development
Hurwitz, J. L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.120 · Cited by 129
Higashikawa, K., Yagi, K., Watanabe, K., Kamino, S., Ueda, M., Hiromura, M., & Enomoto, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109866 · Cited by 118
“A superagonist antibody for CD28 (TGN1412), which directly stimulates T cells, caused life-threatening inflammatory reactions in a London clinical trial [9].”
BackgroundFriesecke, S., Träger, K., Schittek, G. A., Molnár, Z., Bach, F., Kogelmann, K., Bogdanski, R., Weyland, A., Nierhaus, A., Nestler, F., et al. (2017) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-017-0342-5 · Cited by 133
“Cytotoxiceffects with substrate loss in several organs [1] and immune paralysis [2] resulting in an increased susceptibility to secondary infections characterize the consequences of an uncontrolled release of inflammatory mediators.”
BackgroundCostimulation blockade in autoimmunity and transplantation
Vincenti, F. G. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.01.002 · Cited by 112
Immunotherapy in the treatment of non-small cell lung cancer
Sundar, R., Soong, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.05.005 · Cited by 123
“TGN1412, an antibody against CD28 was found to be extremely toxic and has hence no further trials have been conducted with this class of drugs [90].”
Preclinical and clinical safety of monoclonal antibodies
Tabrizi, M. A., & Roskos, L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.05.010 · Cited by 116
Immune-Mediated Adverse Drug Reactions
Uetrecht, J. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800389u · Cited by 110
Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases
CHRISTOPOULOS, P. F., Gjølberg, T. T., Krüger, S., Haraldsen, G., Andersen, J. T., & Sundlisæter, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668207 · Cited by 117
Determinants of the Establishment of Human Immunodeficiency Virus Type 1 Latency
Duverger, A. E., Jones, J., May, J. E., Bibollet‐Ruche, F., Wagner, F. A., Cron, R. Q., & Kutsch, O. (2009) · Journal of Virology · doi:10.1128/jvi.02058-08 · Cited by 123
“Targeted activation of latently infected cells still remains a therapeutic option, but the devastating results from the TGN1412 clinical phase I trial, in which the application of an agonistic anti-CD28 antibody had a near-fatal outcome for all six volunteers, would suggest extremely careful evaluation of this path (3…”
BackgroundHumanized mouse models of immunological diseases and precision medicine
Shultz, L. D., Keck, J., Burzenski, L., Jangalwe, S., Vaidya, S., Greiner, D. L., & Brehm, M. A. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09796-2 · Cited by 109
Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects
Antonia, S. J., Larkin, J., & Ascierto, P. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1457 · Cited by 108
“In a first-in-human phase I trial, TGN1412 administration resulted in a cytokine storm that caused severe adverse events in the six volunteers (30).”
BackgroundRisks and benefits of biologic therapy for inflammatory bowel diseases
D’Haens, G. (2007) · Gut · doi:10.1136/gut.2006.103564 · Cited by 123
Interleukin-6 in Sepsis and Capillary Leakage Syndrome
Krüttgen, A., & Rose‐John, S. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0062 · Cited by 120
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Wang, J., Yuan, R., Song, W., Sun, J., Liu, D., & Li, Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0403-5 · Cited by 107
“Additionally, since both B7 ligands and CD28/CTLA-4 receptors are expressed broadly without tumor specificity and that they play essential roles in the control of general immune homeostasis, targeting this pathway could be met with severe autoimmune toxicities, which was shown to be the case in the clinical trials of…”
BackgroundCytokine release assays: Current practices and future directions
Finco, D., Grimaldi, C., Fort, M., Walker, M., Kiessling, A., Wolf, B., Salcedo, T., Faggioni, R., Schneider, A., Ibraghimov, A., et al. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.009 · Cited by 106
Hynds, R. E., & Giangreco, A. (2013) · Stem Cells · doi:10.1002/stem.1290 · Cited by 106
Low, D. E. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.03.012 · Cited by 106
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 105
Vincenti, F. G., & Kirk, A. D. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02403.x · Cited by 105
“However, CD28-specific antibodies have been shown to have agonistic effects resulting in cytokine release and unacceptable complications (31,32).”
BackgroundYiu, H., Graham, A. L., & Stengel, R. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045027 · Cited by 122
“Critical care and subsequent treatment included dialysis, mechanical ventilation, and, in one case, surgery to counter peripheral ischemia [11,14].”
BackgroundMethodResultInfluentialBojadzic, D., Alcazar, O., & Buchwald, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600372 · Cited by 113
Muller, P., & Brennan, F. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.273 · Cited by 104
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist, M., Kuball, J. H. E., Radstake, T. R. D. J., & Meyaard, L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.131 · Cited by 118
“However, co‑targeting stimulatory receptors can be dangerous, as demonstrated by the outcome of the trial with an agonistic CD28 antibody: this superagonistic antibody induced a cytokine storm and severe clinical problems in healthy volunteers 120 .”
Nanostructured Materials for Intracellular Cargo Delivery
Tay, A. K. P., & Melosh, N. A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00272 · Cited by 105
Cytokines: The Good, the Bad, and the Deadly
Ramani, T., Auletta, C. S., Weinstock, D., Mounho-Zamora, B., Ryan, P. C., Salcedo, T. W., & Bannish, G. (2015) · International Journal of Toxicology · doi:10.1177/1091581815584918 · Cited by 129
Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 102
Advanced model systems and tools for basic and translational human immunology
Wagar, L. E., DiFazio, R. M., & Davis, M. M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0584-8 · Cited by 102
New Insights on OX40 in the Control of T Cell Immunity and Immune Tolerance In Vivo
Xiao, X., Gong, W., Demirci, G., Liu, W., Spoerl, S., Chu, X., Bishop, D. K., Turka, L. A., & Li, X. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101373 · Cited by 102
CD40 and CD80/86 Act Synergistically to Regulate Inflammation and Mortality in Polymicrobial Sepsis
Nolan, A., Weiden, M. D., Kelly, A., Hoshino, Y., Hoshino, S., Mehta, N. N., & Gold, J. A. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-515oc · Cited by 100
“These data are consistent with the observation that stimulation of CD28 with an agonistic mAb in humans can result in a fulminant shocklike state with high lethality (24).”
BackgroundResultEngager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Iwahori, K., Kakarla, S., Velasquez, M. P., Feng, Y., Yi, Z., Gerken, C. P., Song, X., & Gottschalk, S. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.156 · Cited by 102
CD28 Co-Stimulation Down Regulates Th17 Development
Bouguermouh, S., Fortin, G., Baba, N., Rubio, M., & Sarfati, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005087 · Cited by 101
“In support of our in vitro observations, several studies have demonstrated that interfering with B7 co-stimulatory pathways may alter the development or the course of Th17/Th1associated autoimmune diseases in vivo [40].”
ResultA Dormant Microbial Component in the Development of Preeclampsia
Kell, D. B., & Kenny, L. C. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00060 · Cited by 101
Drug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 110
Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?
Heimberger, A. B., & Sampson, J. H. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq169 · Cited by 104
“Thus, in the context of clinical trials of immunotherapeutics, there are little data to support a traditional phase I dose-escalation approach based on toxicity assessment alone.(77) An alternative goal of “dose-escalation” immunotherapeutic trials has been to determine the most effective dose.”
BackgroundMorris, G., Bortolasci, C. C., Puri, B. K., Marx, W., O'Neil, A. E., Athan, E., Walder, K. R., Berk, M., OLIVE, L. S., Carvalho, A. F., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155593 · Cited by 110
van der Walle, C. F. (2011) · Elsevier eBooks · doi:10.1016/c2010-0-64887-5 · Cited by 113
Jhunjhunwala, S., Balmert, S. C., Raimondi, G., Dons, E. M., Nichols, E. E., Thomson, A. W., & Little, S. R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.013 · Cited by 115
“In fact, phase I clinical trials of the superagonistic anti-CD28 Ab (TGN1412) resulted in severe negative reactions (cytokine ‘storm’) in all 6 human subjects who received the Ab [23].”
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Procedure versus process: ethical paradigms and the conduct of qualitative research
Pollock, K. (2012) · BMC Medical Ethics · doi:10.1186/1472-6939-13-25 · Cited by 182
“[55,56].”
First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless
Dresser, R. S. (2009) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2009.00349.x · Cited by 102
Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates
Chapman, K. L., Pullen, N., Coney, L., Dempster, M., Andrews, L., Bajramovic, J. J., Baldrick, P., Buckley, L. A., Jacobs, A., Hale, G., et al. (2009) · mAbs · doi:10.4161/mabs.1.5.9676 · Cited by 109
“Nevertheless, the close relatedness of the NHP to man does not necessarily guarantee that they are the most appropriate species for the development of mAbs as illustrated by the TGN1412 clinical trial in 2006 where the NHP had limited utility in detecting the cytokine storm subsequently observed in the phase 1 clinica…”
BackgroundAlternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals
Bussiere, J. L., Martin, P. L., Horner, M. J., Couch, J. A., Flaherty, M. M., Andrews, L., Beyer, J. C., & Horvath, C. J. (2009) · International Journal of Toxicology · doi:10.1177/1091581809337262 · Cited by 102
“However, when dosed to normal volunteers, TGN1412 resulted in massive cytokine release (a ‘‘cytokine storm’’), accompanied by rapid, severe T-cell depletion (within 1 hour, the earliest time point at which T-cell counts were measured) associated with headache, rigors, myalgia, hypotension, tachycardia, fever, and mult…”
BackgroundComplexities of targeting innate immunity to treat infection
Brown, K. L., Cosseau, C., Gardy, J. L., & Hancock, R. E. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.04.005 · Cited by 106
The highway code of T cell trafficking
Marelli‐Berg, F., Cannella, L., Dazzi, F., & Mirenda, V (2008) · The Journal of Pathology · doi:10.1002/path.2269 · Cited by 97
“In addition, the recent observation that co-stimulatory molecules can regulate T cell trafficking [87] may provide an explanation for the often severe side-effects associated with the therapeutic manipulation of these molecules [122,123].”
BackgroundRole of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis
Buc, M. (2013) · Mediators of Inflammation · doi:10.1155/2013/963748 · Cited by 114
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R., Schulick, R., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 97
“This concept was first demonstrated through the costimulatory receptor CD28, which binds to the ligands B7-1 (CD80) and B7-2 (CD86) on antigen-presenting cells (APCs), allowing for T cell activation [2,3].”
BackgroundInfluentialMultiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes
Wiendl, H., & Hohlfeld, R. (2009) · Neurology · doi:10.1212/01.wnl.0000344417.42972.54 · Cited by 96
Schrand, B., Berezhnoy, A., Brenneman, R., Williams, A., Levay, A., Kong, L.-Y., Rao, G., Zhou, S., Heimberger, A. B., & Gilboa, E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0007 · Cited by 96
“Results were associated with high frequencies of objective responses, yet adverse effects became significant at the highest dose used causing liver toxicity that resulted in two fatalities [10, 11].”
BackgroundTumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
Waite, J. C., Wang, B., Haber, L., Hermann, A., Ullman, E., Ye, X., Dudgeon, D., Slim, R., Ajithdoss, D. K., Godin, S. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba2325 · Cited by 96
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
Amatore, F., Gorvel, L., & Olive, D. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1444753 · Cited by 98
Vascular endothelium and graft-versus-host disease
Biedermann, B. C. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.02.003 · Cited by 95
Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients
Waldron-Lynch, F., Henegariu, O., Deng, S., Preston-Hurlburt, P., Tooley, J., Flavell, R., & Herold, K. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003401 · Cited by 94
Moyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.